MAR-AFATINIB

Product Overview

About MAR-AFATINIB

MAR-AFATINIB is a prescription medication containing the active ingredient Afatinib (Afatinib Dimaleate), a tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung cancer (NSCLC).

Key Benefits & Uses

• Treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
• Treatment of NSCLC with EGFR exon 20 T790M mutation, as detected by an FDA-approved test, in patients whose tumors progressed on or after EGFR tyrosine kinase inhibitor therapy.
• Diagnosis and treatment of NSCLC with EGFR exon 20 T790M mutation, as detected by an FDA-approved test, in patients whose tumors progressed on or after EGFR tyrosine kinase inhibitor therapy.

Active Ingredient & Action

Afatinib (Afatinib Dimaleate) works by inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and other related kinases, thereby blocking the signal transduction pathways that lead to cell proliferation and survival. This results in the inhibition of tumor growth and the induction of apoptosis in cancer cells.

Important Notes

MAR-AFATINIB is available only by prescription and should be used under the guidance of a qualified healthcare professional. Patients should be informed of the potential risks and benefits associated with the use of this medication, including the risk of adverse reactions and the importance of regular monitoring of liver function and other vital signs.